Metabolomics in liver diseases: A novel alternative for liver biopsy?

作     者：Yasuo Tanaka 

作者机构：Department of GastroenterologyNational Center for Global Health and MedicineTokyo 162-8655Japan 

出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)

年 卷 期：2024年第16卷第1期

页      面：12-16页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by JSPS KAKENHI No.JP21K07906 

主　　题：Metabolomics Hepatitis C virus Liver fibrosis Liver cirrhosis Serum biomarker 

摘      要：Hepatitis C virus(HCV)remains a significant public health problem as it can cause acute and chronic *** HCV infection is a major cause of liver fibrosis,and evaluation of liver fibrosis is essential because the prognosis of patients with chronic HCV infection is closely related to the stage of *** fibrosis is traditionally evaluated based on pathological analysis of biopsy specimens,which is considered the gold ***,liver biopsy is invasive and susceptible to sampling error and inter-and intraobserver variation in pathological interpretation;it is also ***,noninvasive diagnostic investigations have been developed,including the use of fibrotic markers,scoring systems based on routine blood tests,and transient elastography with magnetic resonance imaging or ***,metabolomics,an emerging technology,has been used to detect the fibrosis *** this editorial,I comment on the article titled“Metabolomics in chronic hepatitis C:Decoding fibrosis grading and underlying pathwaysby Ferrasi et al published in the recent issue of the World Journal of Hepatology.I discuss previous studies on the use of metabolome analysis for the diagnosis of HCV-related liver fibrosis and the potential development of biopsy-free diagnostic techniques.